242 related articles for article (PubMed ID: 27505670)
21. Maintaining cell identity: PRC2-mediated regulation of transcription and cancer.
Comet I; Riising EM; Leblanc B; Helin K
Nat Rev Cancer; 2016 Dec; 16(12):803-810. PubMed ID: 27658528
[TBL] [Abstract][Full Text] [Related]
22. Looping around Bcl6 in Germinal Center to Sharpen B Cell Immunity.
Hu G; Zhao K
Immunity; 2016 Sep; 45(3):459-461. PubMed ID: 27653595
[TBL] [Abstract][Full Text] [Related]
23. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
24. BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.
Valls E; Lobry C; Geng H; Wang L; Cardenas M; Rivas M; Cerchietti L; Oh P; Yang SN; Oswald E; Graham CW; Jiang Y; Hatzi K; Agirre X; Perkey E; Li Z; Tam W; Bhatt K; Leonard JP; Zweidler-McKay PA; Maillard I; Elemento O; Ci W; Aifantis I; Melnick A
Cancer Discov; 2017 May; 7(5):506-521. PubMed ID: 28232365
[TBL] [Abstract][Full Text] [Related]
25. A Novel Role of Chromodomain Protein CBX8 in DNA Damage Response.
Oza J; Ganguly B; Kulkarni A; Ginjala V; Yao M; Ganesan S
J Biol Chem; 2016 Oct; 291(44):22881-22893. PubMed ID: 27555324
[TBL] [Abstract][Full Text] [Related]
26. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Reddy A; Zhang J; Davis NS; Moffitt AB; Love CL; Waldrop A; Leppa S; Pasanen A; Meriranta L; Karjalainen-Lindsberg ML; Nørgaard P; Pedersen M; Gang AO; Høgdall E; Heavican TB; Lone W; Iqbal J; Qin Q; Li G; Kim SY; Healy J; Richards KL; Fedoriw Y; Bernal-Mizrachi L; Koff JL; Staton AD; Flowers CR; Paltiel O; Goldschmidt N; Calaminici M; Clear A; Gribben J; Nguyen E; Czader MB; Ondrejka SL; Collie A; Hsi ED; Tse E; Au-Yeung RKH; Kwong YL; Srivastava G; Choi WWL; Evens AM; Pilichowska M; Sengar M; Reddy N; Li S; Chadburn A; Gordon LI; Jaffe ES; Levy S; Rempel R; Tzeng T; Happ LE; Dave T; Rajagopalan D; Datta J; Dunson DB; Dave SS
Cell; 2017 Oct; 171(2):481-494.e15. PubMed ID: 28985567
[TBL] [Abstract][Full Text] [Related]
27. Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies.
Tanaka T; Nakajima-Takagi Y; Aoyama K; Tara S; Oshima M; Saraya A; Koide S; Si S; Manabe I; Sanada M; Nakayama M; Masuko M; Sone H; Koseki H; Iwama A
J Exp Med; 2017 Oct; 214(10):2901-2913. PubMed ID: 28827447
[TBL] [Abstract][Full Text] [Related]
28. Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene.
Lefebure M; Tothill RW; Kruse E; Hawkins ED; Shortt J; Matthews GM; Gregory GP; Martin BP; Kelly MJ; Todorovski I; Doyle MA; Lupat R; Li J; Schroeder J; Wall M; Craig S; Poortinga G; Cameron D; Bywater M; Kats L; Gearhart MD; Bardwell VJ; Dickins RA; Hannan RD; Papenfuss AT; Johnstone RW
Nat Commun; 2017 Mar; 8():14581. PubMed ID: 28262675
[TBL] [Abstract][Full Text] [Related]
29. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
30. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Béguelin W; Teater M; Meydan C; Hoehn KB; Phillip JM; Soshnev AA; Venturutti L; Rivas MA; Calvo-Fernández MT; Gutierrez J; Camarillo JM; Takata K; Tarte K; Kelleher NL; Steidl C; Mason CE; Elemento O; Allis CD; Kleinstein SH; Melnick AM
Cancer Cell; 2020 May; 37(5):655-673.e11. PubMed ID: 32396861
[TBL] [Abstract][Full Text] [Related]
31. BCOR involvement in cancer.
Astolfi A; Fiore M; Melchionda F; Indio V; Bertuccio SN; Pession A
Epigenomics; 2019 May; 11(7):835-855. PubMed ID: 31150281
[No Abstract] [Full Text] [Related]
32. Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.
Yusufova N; Kloetgen A; Teater M; Osunsade A; Camarillo JM; Chin CR; Doane AS; Venters BJ; Portillo-Ledesma S; Conway J; Phillip JM; Elemento O; Scott DW; Béguelin W; Licht JD; Kelleher NL; Staudt LM; Skoultchi AI; Keogh MC; Apostolou E; Mason CE; Imielinski M; Schlick T; David Y; Tsirigos A; Allis CD; Soshnev AA; Cesarman E; Melnick AM
Nature; 2021 Jan; 589(7841):299-305. PubMed ID: 33299181
[TBL] [Abstract][Full Text] [Related]
33. OFCD syndrome and extraembryonic defects are revealed by conditional mutation of the Polycomb-group repressive complex 1.1 (PRC1.1) gene BCOR.
Hamline MY; Corcoran CM; Wamstad JA; Miletich I; Feng J; Lohr JL; Hemberger M; Sharpe PT; Gearhart MD; Bardwell VJ
Dev Biol; 2020 Dec; 468(1-2):110-132. PubMed ID: 32692983
[TBL] [Abstract][Full Text] [Related]
34. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.
Venturutti L; Teater M; Zhai A; Chadburn A; Babiker L; Kim D; Béguelin W; Lee TC; Kim Y; Chin CR; Yewdell WT; Raught B; Phillip JM; Jiang Y; Staudt LM; Green MR; Chaudhuri J; Elemento O; Farinha P; Weng AP; Nissen MD; Steidl C; Morin RD; Scott DW; Privé GG; Melnick AM
Cell; 2020 Jul; 182(2):297-316.e27. PubMed ID: 32619424
[TBL] [Abstract][Full Text] [Related]
35. BCL6 corepressor contributes to Th17 cell formation by inhibiting Th17 fate suppressors.
Kotov JA; Kotov DI; Linehan JL; Bardwell VJ; Gearhart MD; Jenkins MK
J Exp Med; 2019 Jun; 216(6):1450-1464. PubMed ID: 31053612
[TBL] [Abstract][Full Text] [Related]
36. Gene of the month: BCOR.
Aldera AP; Govender D
J Clin Pathol; 2020 Jun; 73(6):314-317. PubMed ID: 32161069
[TBL] [Abstract][Full Text] [Related]
37. Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.
Sportoletti P; Sorcini D; Guzman AG; Reyes JM; Stella A; Marra A; Sartori S; Brunetti L; Rossi R; Papa BD; Adamo FM; Pianigiani G; Betti C; Scialdone A; Guarente V; Spinozzi G; Tini V; Martelli MP; Goodell MA; Falini B
Leukemia; 2021 Jul; 35(7):1949-1963. PubMed ID: 33159179
[TBL] [Abstract][Full Text] [Related]
38.
Tara S; Isshiki Y; Nakajima-Takagi Y; Oshima M; Aoyama K; Tanaka T; Shinoda D; Koide S; Saraya A; Miyagi S; Manabe I; Matsui H; Koseki H; Bardwell VJ; Iwama A
Blood; 2018 Dec; 132(23):2470-2483. PubMed ID: 30228234
[No Abstract] [Full Text] [Related]
39. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures.
Kotlov N; Bagaev A; Revuelta MV; Phillip JM; Cacciapuoti MT; Antysheva Z; Svekolkin V; Tikhonova E; Miheecheva N; Kuzkina N; Nos G; Tabbo F; Frenkel F; Ghione P; Tsiper M; Almog N; Fowler N; Melnick AM; Leonard JP; Inghirami G; Cerchietti L
Cancer Discov; 2021 Jun; 11(6):1468-1489. PubMed ID: 33541860
[TBL] [Abstract][Full Text] [Related]
40. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Ennishi D; Takata K; Béguelin W; Duns G; Mottok A; Farinha P; Bashashati A; Saberi S; Boyle M; Meissner B; Ben-Neriah S; Woolcock BW; Telenius A; Lai D; Teater M; Kridel R; Savage KJ; Sehn LH; Morin RD; Marra MA; Shah SP; Connors JM; Gascoyne RD; Scott DW; Melnick AM; Steidl C
Cancer Discov; 2019 Apr; 9(4):546-563. PubMed ID: 30705065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
